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Levels of cardiovascular mortality and morbidity are high
in chronic kidney disease (CKD) with a graded inverse
relationship with glomerular filtration rate.1,2 This has a
large public health impact because of the high prevalence
of early-stage CKDwhich affects about 1 in 7 people in the
United States.3 Although patients with CKD have a
clustering of atherosclerotic risk factors, the majority of
deaths are due to heart failure and arrhythmia.4 This
suggests that the underlyingmechanism for heart disease in
patients with CKD is not coronary atherosclerosis but
myocardial disease, so-called uremic cardiomyopathy. In
the early stages of CKD, sensitive markers of systolic
(strain) and diastolic function are often abnormal, and there
is an increased prevalence of left ventricular hypertrophy
(LVH).5,6 Causative factors are thought to include increased
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ences, and circulating factors including mediators of the
renin-angiotensin-aldosterone system. These factors are
already present in stage 2 to 3 CKD and provide potential
targets for treatment aimed at preventing the development
and progression of myocardial hypertrophy and fibrosis.7
Aldosterone is as a key mediator of cardiovascular disease
in many conditions including heart failure and CKD. This
hormone causes vascular and myocardial injury and fibrosis,
particularly in the presence of sodium excess as occurs in
CKD.8 Mineralocorticoid receptor blocker (MRB) drugs
ameliorate these actions in cellular and animal models and
improve clinical outcomes in peoplewith heart failure.8 Like
heart failure, CKD is characterized by sodium overload and
high aldosterone concentrations due to aldosterone escape
(unsuppressed levels of aldosterone despite chronic sodium
overload) and aldosterone breakthrough (high circulating
aldosterone levels despite suppression with angiotensin-
converting enzyme [ACE] inhibitors or angiotensin receptor
blocker [ARB] drugs).4 In the CRIB-2 trial of 112 patients
with stages 2 and 3 CKD, we showed that, compared with
placebo, spironolactone reduced LV mass, arterial stiffness,
and collagen turnover and improved myocardial diastolic
function.9,10 As blood pressure was also reduced by
spironolactone with a mean fall in systolic pressure of
11 mmHg, it is possible that the effects of spironolactone on
cardiovascular structure and function were nonspecific and
mediated by blood pressure lowering alone. To address
whether the benefits of spironolactone in CRIB-2 were
specific to mineralocorticoid blockade or as a result of a
reduction in blood pressure, we designed the Spironolac-
tone in Chronic KidneyDisease (SPIRO-CKD) trial to include
an active control drug to lower blood pressure to similar
levels. Chlorthalidone was chosen as the control drug
because of its proven antihypertensive action in patients
with early-stage CKD with an effect size in the ALLHAT
substudy in this patient group about equal to that of
spironolactone in CRIB-2.11 The SPIRO-CKD trial was
initially designed to investigate the hypothesis that spirono-
lactone is superior to chlorthalidone in the reduction of a
co-primary end point consisting of LV mass and arterial
stiffness. Recruitment was slower than anticipated because
of smaller numbers of patients with early-stage CKD being
reviewed routinely in a number of participating centers.
Following discussions with the British Heart Foundation
(funding body) and the Trial Steering Committee, it was
decided that it would not be possible to recruit a sample size
sufficient to provide adequate statistical power to detect a
change in arterial stiffness. The study design has therefore
changed to one with a single primary end point of LV mass.Methods
Study design
This multicenter, prospective, randomized, open-label,
blinded end point (PROBE) clinical trial was initiallydesigned to compare the effects of 40 weeks of treatment
with spironolactone 25 mg once daily to chlorthalidone
25 mg once daily on the co-primary end point of change
in LV mass using cardiac magnetic resonance imaging
(MRI) and pulse wave velocity (PWV) in patients with
stages 2 and 3 CKD, without known cardiovascular
disease or diabetes mellitus and on established treatment
with an ACE inhibitor or an ARB with controlled blood
pressure on study entry. Nested substudies were also
designed to compare the effects of these drugs on
changes in LV systolic and diastolic deformation (global
longitudinal strain) and in LV interstitial fibrosis (T1
mapping), both measured noninvasively by cardiac MRI.
Calculation of estimated glomerular filtration rate (eGFR)
has been performed using the 4-variable Modification of
Diet in Renal Disease formula. CKD stages 2 and 3 have
been defined as an eGFR of 60-89 mL/min/1.73 m2 in the
presence of another abnormality, for example, albumin-
uria or a structural abnormality of the kidney, and
30-59 mL/min/1.73 m2, respectively.12 At the time of
recruitment, creatinine was measured from blood tests
performed within the last 12 months on 2 occasions at
least 90 days apart. Details of the inclusion and exclusion
criteria, and the study outcome measures are listed in
Tables I and II, respectively. The academic centers
participating in the trial will be the University of
Birmingham, the University of Cambridge, University College
London, and the University of Edinburgh, UK. Patients have
been recruited fromtheQueenElizabethHospital Birmingham;
Addenbrookes Hospital, Cambridge; the Royal Free Hospital,
London; theWesternGeneral Hospital Edinburgh; and primary
care practices in Edinburgh.
The trial started recruitment in June 2014 and aimed to
recruit 350 patients over a 2-year period. However, the
rate of recruitment was slower than anticipated, and it
became evident by November 2015 that recruitment of
this number would not be completed within the funded
time, and the decision was taken to change the study
design to one with the single primary end point of change
in LV mass. This allowed a sample size which could be
recruited within the funded time frame (see sample size
calculations section). This decision was made following
discussions with the funder, that is, the British Heart
Foundation; the Trial Management Group; and the
Trial Steering Committee who remain blind to any interim
data analyses.
Ethical approval for this study was awarded by theWest
Midlands National Research Ethics Service Committee in
September 2013 (13/WM/0304). The study is funded by
the British Heart Foundation (SP/12/8/29620) and is
registered with Medicines and Healthcare products
Regulatory Agency (Clinical Trials Authorization No.
21761/0295/001-0001). The authors are solely responsi-
ble for the design and conduct of this study, all study
analyses, the drafting and editing of the article, and its
final contents.
Table I. Inclusion and exclusion criteria
Inclusion criteria
Age N18 y and willing to undergo investigations
CKD stage 2 or 3 (eGFR 30-89 mL/min/1.73 m2) from blood tests performed within the last 12 m on 2 occasions at least 90 d apart.
(For stage 2 CKD, no criteria for urinary or blood test or structural abnormalities were mandated;
these criteria were left to the discretion of the local principal investigator.)
Controlled blood pressure (no current indication for additional antihypertensive therapy in the opinion of the local principal investigator)
On established (N6 wk) treatment with ACE inhibitors or ARBs
Clinically stable (no hospital admission or other significant acute illness within 3 m) and no recent (b6 m) acute myocardial infarction
Females of childbearing potential must not be pregnant or breast feeding, and must agree to avoid pregnancy and to use adequate,
medically approved contraceptive precautions during and for 6 wk following the last dose of study treatment.
Males with a partner of childbearing potential must agree to use medically approved contraception during and for 6 wk following
the last dose of study treatment.
Exclusion criteria
Diabetes mellitus
Clinical evidence of hypovolemia
On current regular treatment with nonsteroidal anti-inflammatory drugs or other agents (except ACE inhibitors, ARBs, or low-dose aspirin)
that might cause a reduction in eGFR
Recent (b6 m) acute myocardial infarction or other major adverse cardiovascular event (STEMI, NSTEMI, unstable angina,
coronary revascularization, stroke, transient ischemic attack)
Known LV systolic dysfunction (ejection fraction b50%) or severe valvular heart disease or evidence of heart failure
Active malignant disease with a life expectancy of b5 y
Previous hyperkalemia (K+ ≥6.0 mmol/L) without precipitating cause
Serum K+ N5.0 at entry
Serum sodium b130 mmol/L at entry
Atrial fibrillation on screening ECG
Current treatment with spironolactone or other mineralocorticoid receptor blocker
Use of a thiazide or loop diuretic in the 6 wk prior to enrolment
Pregnant or breastfeeding
Known alcohol or drug abuse
Active chronic diarrhea
Recent active gout (within 3 m)
Acute kidney injury in previous 3 m
Documented Addison disease
Treatment with fludrocortisone, cotrimoxazole, or lithium
Combination treatment with ACE inhibitor and ARB
Office blood pressure b115 mm Hg systolic or b50 mm Hg diastolic
Office blood pressure uncontrolled and requiring urgent nontrial treatment
Unable to provide informed consent
STEMI, ST-elevation myocardial infarction; NSTEMI, non–ST-elevation myocardial infarction; ECG, electrocardiogram.
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Recruitment of 154 patients was completed by 31
December 2016. Eligible patients (Table I) were identi-
fied using hospital and primary care medical records. All
recruitment took place within hospital outpatient clinics
in the aforementioned institutions in 2 stages. Firstly, all
patients apparently fulfilling the eligibility criteria were
asked for written consent for additional screening
procedures to be undertaken. Screening procedures
were as follows:
1. Ensuring that potential participants met the study's
inclusion and exclusion criteria.
2. Physical examination to check pulse, office blood
pressure, and signs of hypovolemia, and a cardiovas-
cular examination to exclude signs of heart failure or
valvular disease. Echocardiography was performed
only in cases of clinical uncertainty about the
presence of heart failure or valve disease.3. Recording an electrocardiogram.
4. Blood tests for routine biochemical and hematolog-
ical parameters including eGFR.
5. Femalesofchild-bearingpotentialunderwentapregnancytest.
When patients fulfilled the eligibility criteria, informed
written consent was obtained for randomization into the
main SPIRO-CKD trial in keeping with the principles set
out by the Declaration of Helsinki.
Run-in phase
For those patients wanting to take part but not
immediately eligible because they are either on existing
diuretic therapy or not taking ACE inhibitor or ARB
therapy or taking both of these agents, a 4- to 6-week
run-in phase is used. For patients on existing loop or
thiazide diuretic therapy who wish to take part in the
trial, after obtaining consent, diuretic therapy is stopped,
and the patient is reviewed after 4 weeks to ensure that
Table II. Primary and secondary outcome measures
Primary outcome measures
Change between baseline and 40 wk in LV mass measured by cardiac MRI
Secondary outcome measures
Change between baseline and 40 wk in arterial stiffness measured by carotid-femoral PWV
Change between baseline and 40 wk in office, central, and ambulatory blood pressures
Change between baseline and 40 wk in urinary albumin-creatinine ratio
Changes between baseline and 40 wk in LV volumes and systolic function
Changes between baseline and 40 wk in plasma NT-pro-BNP
Incidence of hyperkalemia
Change between baseline and 40 wk in eGFR
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not on ACE inhibitor or ARB therapy, after obtaining
consent, an ACE inhibitor or ARB of the physician's
choice is introduced and titrated to a well-tolerated
therapeutic dose over a 4-week period. The patient is
then reviewed to ensure eligibility. For patients on dual
ACE inhibitor and ARB therapy, after obtaining consent,
either the ACE inhibitor or the ARB is stopped. Patients
are then reviewed to ensure eligibility. Those patients
who fulfill all entry criteria are consented and randomized
into the main SPIRO-CKD trial.
Randomization
Once informed consent is received and the baseline
assessments completed, patients are entered into the
main SPIRO-CKD trial. Participants are randomized in a
1:1 ratio to either spironolactone (25 mg once a day) or
chlorthalidone (half a 50-mg tablet once a day, as there
are no 25-mg tablets available for use in the UK) for
40 weeks without blinding. A secure central randomiza-
tion service was provided by the Birmingham Clinical
Trials Unit (University of Birmingham) using a
computer-generated program, using a minimization
algorithm to ensure balance between the arms with
regard to the important clinical variables of blood
pressure, age, and gender. Compliance with treatment
is monitored by study coordinators using tablet counting.
Investigations
The trial design and schedule of investigations are
summarized in Figure 1, and further information is
available in Appendix 1. All baseline investigations have
now been completed, and patients are being followed as
per the study schedule. The trial consists of a 40-week
period of randomized treatment followed by a 6-week
period designed to detect effects caused by prolonged
treatment rather than direct pharmacological effects. At
the baseline visit, informed consent is taken, and weight
and heart rate are recorded. Office blood pressure is
measured using a British Hypertension Society–validated
semiautomated device on 3 occasions in the seated
position after 5 minutes of rest with research staff present
during the measurement; the mean of the last 2 readingsis used for analysis. Participants undergo 24-hour
ambulatory blood pressure monitoring at baseline using
a British Hypertension Society–validated oscillometric
recorder set to make measurements every 30 minutes
between 8:00AM and 10:00PM and hourly during the
remaining hours. In addition, all patients undergo blood
and urine tests, a cardiac MRI scan, and PWV and pulse
wave analysis testing, after which the trial medication is
given to the patient. More detail on the study investiga-
tions is given below. The measurement and analysis of
end points are performed by observers blinded to
treatment allocation.
Participants are followed up at weeks 1, 2, 4, 8, 24, 40,
and 46 postrandomization. In the event of participants
being unable to attend for scheduled visits because of
other intercurrent issues, they are asked to attend at the
closest possible date, whenever possible within 2 weeks
of the due date. Where a participant cannot attend their
week 40 study visit and investigations, they are asked
either to undertake this visit up to 3 weeks before the due
date or, alternatively, to continue the study medication
until the scheduled investigations can be undertaken
(whenever possible within 4 weeks of the planned date).
The investigations listed below are carried out at time
intervals during the trial as listed in Figure 1 and
Appendix 1. All end points including SphygmoCor and
cardiac MRI values are measured by investigators blinded
to treatment allocation.
Blood and urine. Routine hematological and bio-
chemical parameters, including plasma lipids, are record-
ed at weeks 0, 1, 2, 4, 8, 24, 40, and 46 as indicated in
Appendix 1. Plasma is stored for measurement assays of
NT-pro-BNP and other biomarkers. Separate consent is
also sought to take blood for DNA extraction to allow
future analysis for genetic influences on kidney disease
and response to treatment. Urine samples are collected
for analysis of albumin-creatinine ratio and other
biomarkers.
Pulse wave velocity. SphygmoCor (AtCor Medical,
Sydney, Australia) studies are performed at weeks 0, 4,
24, 40, and 46. Carotid femoral PWV is the current
standard technique for measuring aortic stiffness.13
Subjects are studied in a quiet, temperature-controlled
Figure 1
Trial procedure flowchart.
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pressure ismeasured3 times in thenondominant arm, and the
final 2 readings are averaged and entered into the machine
software. PWV (SphygmoCor) is determined by sequential
acquisition of pressure waveforms from the carotid and
femoral arteries by using a high-fidelity micromanometer
(SPC-301; Millar Instruments, Houston, TX).14,15 The path
length is calculated by subtracting the distance between the
sternal notch and the carotid recording site from the distance
between the sternal notch and the femoral site.13
Pulse wave analysis. Participants are requested to
rest in a supine position for 5 minutes before measuring
seated blood pressure 3 times in the nondominant arm.
Again, an average of the final 2 blood pressures is entered
into the machine software prior to undertaking applana-
tion tonometry to record high-fidelity arterial pressure
waveforms, from which indices relating to large artery
stiffness can be calculated.14,16 A micromanometer is
used to flatten but not occlude the radial artery of the
nondominant arm using gentle pressure. An averaged
peripheral waveform and the corresponding central
waveform are generated after 11 seconds of data capture.
The central waveform will then be analyzed to determine
the augmentation index (the difference between the
second and first peaks of the central pressure waveform,
expressed as a percentage of the pulse pressure) and
central aortic pressures. This method has been shown to
be reproducible both in healthy subjects and in patients
with CKD.14,16
Cardiac MRI. Cardiac MRI is performed using standard
clinical 1.5-T (Siemens Aera and Avanto—London,
Birmingham; GE Discovery MR450—Cambridge) or 3-T
(Siemens Verio—Edinburgh) scanners at each site at
weeks 0 and 40.
Image acquisition. The standard protocol is estimated to take
30 minutes. Serial contiguous short-axis cines are piloted from
the vertical long-axis and horizontal short-axis images of the left
and right ventricles for assessment of dimensions, volumes, LV
function (ejection fraction, deformation), andmass in linewith
the standard cardiovascular MRI protocol.17,18 Regional aortic
distensibility will be assessed on cine imaging in the
proximal ascending aorta using the following formula:
aortic distensibility = Δaortic area/(minimum aortic
area × pulse pressure). Peripheral blood pressure is
performed synchronously in triplicate at the brachial artery
at the time of scanning for determination of pulse pressure.
Subjects are also asked for consent to participate in
additional cardiac MRI substudies (detailed below). Partic-
ipation in both substudies lengthens the cardiac MRI scan
duration to approximately 40 and 50 minutes respectively.
Substudy A: tagging (cine spatial modulation of
magnetization). Cardiac MRI is used to assess regional
myocardial function (deformation) and is the recognized
reference standard for measuring strain. This sensitive
measure of regional and global LV contractile function
permits the early detection of subtle LV dysfunction whichprecedes decreases in ejection fraction.19-21 Cine spatial
modulation of magnetization is used to generate a uniform
grid pattern with 8-mm tag separation on the LV myocardi-
um at 3 short-axis sections (basal, mid, and apex) and the
horizontal long-axis image using a fast field echo multishot
sequence (minimumnumber of 15 phases per cardiac cycle)
with prospective electrocardiogram gating.
Substudy B. T1 mapping. T1mapping usingmodified
Look-Locker inversion recovery sequence is performed to
characterize themyocardial tissue and quantify the extent of
diffuse interstitial fibrosis.22,23 Pixel-based T1 maps will be
reconstructed using inline motion correction in the LV
horizontal long axis. Basal and mid short-axis slices will be
acquiredbefore and15 minutes after contrast administration
for myocardial T1 times and calculation of extracellular
volume (ECV) using a 5(3)3 sampling protocol- (average
breath hold 10-15 seconds). A single, weight-adjusted dose
(0.15 mmol/kg) of nonionic, macrocyclic intravenous gad-
olinium contrast (Gadavist; Bayer Healthcare, Berkshire,
England) is given to assess coarse irreversible fibrosis (late
gadolinium enhancement) using standard inversion recov-
ery imaging. In the event of a fall in eGFR to b30 mL/min/
1.73 m2, gadolinium contrast will not be administered on
safety grounds.
Image analysis. Analysis of ventricular volumes, function, and
mass is performed offline using cvi42 software (Circle
Cardiovascular Imaging, Calgary, Canada) at a central cardiac
MRI laboratory by a single experienced clinician blinded to
all trial data. Measurement of aortic cross-sectional area in
systole and diastole is assessed using automated software
(Matlab; MathWorks Inc, Natick, MA).24 Measurement of
aortic distensibility using cardiac MRI has low intraobserver
variability and good reproducibility.25 Tagging analysis is
performed using CIMTag2D; University of Auckland, New
Zealand and Tissue Tracking, cvi42 for LV strain, strain rate,
and torsion calculation.33 For T1 mapping, myocardial and
blood relaxation times pre- and 15 minutes after gadolinium
contrast aremeasuredoffline to calculate nativeT1 times and
ECV using cvi42 software.26 Segmental and global T1 values
are obtained using the AHA 6 segment model in short-axis
slices and a manual region of interest in the basal septum
from the 4-chamber image.Meticulous carewill be taken to
avoid the blood-myocardial boundary (10% offset from
both the epicardial and endocardial borders) and any areas
of LGE. ECV will be calculated using myocardial and blood
T1 values before and after contrast using the following
validated formula27:
ECV ¼ λ 1–Hctð Þ:
Hct refers to the hematocrit recorded on a venous
blood sample at the time of scan, ΔR1 = 1/T1 time
postcontrast – 1/T1 time precontrast. Lambda (λ) refers
to (1/T1 myocardium postcontrast – 1/T1 myocardium
precontrast)/(1/T1 blood postcontrast – 1/T1 blood
precontrast). Normal reference ranges for T1 and ECV
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from a previously published study.28
Withdrawal
Patients may withdraw consent from the study at any
time. Patients may also withdraw from trial treatment but
continue with study follow-up and data collection as per
the protocol.
If the withdrawal is initiated by a health care
professional, full details for the reason for withdrawal
are recorded on the case report forms. In all other cases, a
simple statement reflecting patient preference is noted.
Pharmacovigilance
This trial is categorized by the Medicines and Health-
care products Regulatory Agency as type A (no higher
than the risk of standard medical care). Patients are being
followed up closely throughout this study, and an
ongoing evaluation of risk will continue throughout the
recruitment period. Both spironolactone and chlorthali-
done are considered investigational medicinal products
(IMPs) within SPIRO-CKD trial. Any adverse events or
serious adverse events that occur during this trial are
reportable to the SPIRO-CKD Trials Office at the trials unit
up to 6 weeks following last administration of the IMP. Any
suspectedunexpected serious adverse reactions related to the
IMP will be reported irrespective of how long after IMP
administration the reaction occurred. Responses to abnor-
malities of serum sodium, potassium, and eGFRwill be guided
by predetermined management plans (see Appendix 2).
Blood pressure monitoring
To confirm or deny the trial hypothesis, it is essential
that the change in blood pressure during the treatment
period is not significantly different in each arm of the
trial. A tight blood pressure target was thought imprac-
tical; instead, a blood pressure monitoring committee
(BPMC) reviews the blood pressure data after each block
of 20 patients for the first 100 patients and then after each
block of 30 patients to the end of trial recruitment. The
precise frequency of review may change on the advice of
the BPMC following its independent review of the data.
Patients enter the trial with controlled blood pressure so
that there are not anticipated to be clinical reasons for
adding further drugs for blood pressure control during the
randomized treatment phase. In the event of a difference in
blood pressure change becoming evident, the BPMC will
advise on changes to medication in either arm.
Data Monitoring Committee
An independent Data Monitoring Committee (DMC)
has been convened for the trial. Interim analyses of major
outcome measures and safety data are conducted and
provided in strict confidence to the DMC. Any decision to
stop the trial early will be based on the balance of efficacy
and safety.TheDMCadvises the chair of theTrial SteeringCommittee
if, in its view, any of the randomized comparisons in the trial
have provided both(a) proof beyond reasonable doubt that
for all, or for some, types of participant, 1 particular
intervention is definitely indicated or definitely contraindi-
cated in terms of a net difference of themajor end point and
(b) evidence that might reasonably be expected to influence
the patient management of many clinicians who are already
aware of the other main trial results.
Appropriate criteria of proof beyond reasonable doubt
cannot be specified precisely, but a difference of at least
P b .001 (similar to a Haybittle-Peto stopping boundary)
in an interim analysis of a major end point may be
required to justify halting, or modifying, the study
prematurely. If this criterion were to be adopted, it
would have the practical advantage that the exact
number of interim analyses would be of little importance,
so no fixed schedule is proposed. Given these relatively
strict stopping criteria, no adjustment for multiple testing
(to control the overall type I error rate) is proposed.
Sample size
Data from the CRIB-2 study has been used to inform the
sample size.9 The SD of change in arterial stiffness measured
by PWVwas 1.0 m/s in the spironolactone group and 0.9 m/s
in the placebo group (with a mean difference between
groups of 0.7 m/s). Using the larger of these SDs (1.0 m/s)
for the sample size, to detect aminimum relevant difference
(MRD) of 0.4 m/s (the smallest difference that is of clinical
significance and that can be detected within the limits of
accuracy of the equipment used) in PWV (with 90% power,
2-sided α = .025) required 157 per arm. Allowing for 10%
dropout, this required recruitment of 350 participants. The
SD of change in LV mass was 13 g in the spironolactone
groupand11 g in theplacebogroup (with ameandifference
between groups of 17 g). Again, using the larger of these SDs
(13 g) for the sample size calculation, to detect an MRD of
7 g in LV mass (with 90% power, 2-sided α = .025)
required 87 per arm. Allowing for 10% dropout, this
required recruitment of 200 participants.
The initial design of the study used a co-primary end point
of change in LV mass and change in PWV. A sample size of
350 patients was planned to give 90% power to detect a
difference in PWV and N90% power to detect a change in LV
masswith aP value of .025.When it became evident that this
sample size was not achievable within the funded time, the
primary outcome of the studywas changed to the single end
point of change in LVmass again using anMRDof 7 g.With a
2-sided P value of .05 and a power of 85%, it was calculated
that 63 patients per groupwould be required. Allowing for a
15%dropout andmissing data, this requires 150 participants.
Statistical analysis
The primary comparison groups are composed of those
randomized to spironolactone and those randomized to
chlorthalidone. All analyses will be based on the
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the treatment groups to which they were allocated
irrespective of compliance with the randomized allocated
treatment, and all patients will be included in the
analyses. For all tests, summary statistics (eg, mean
differences, relative risks) will be reported, and 95% CIs
will be constructed where appropriate. A P value of b.05
will be considered statistically significant, and there will
be no adjustment for multiple comparisons.
Primary outcome analysis
LVmass is measured at baseline and 40 weeks. Anymissing
cardiac MR data will be counted as missing in the first
instance. A regressionmodelwith LVmass at 40 weeks as the
outcome variable, and treatment group and baseline LV mass
included as covariates in the model will be fitted. Results will
bepresentedas ameandifferencebetweengroupswith a95%
CI. These analyses assume that the data will be normally
distributed (as is expected). Details of nonparametric analysis
methods thatwill be used should the assumption of normality
not hold will be provided in the Statistical Analysis Plan.
Secondary outcome analysis
Arterial stiffness is measured at baseline and at weeks 4,
24, and 40. The primary analysis for arterial stiffness will
be as per the primary outcome. A regression model with
arterial stiffness at 40 weeks as the outcome variable, and
treatment group and baseline arterial stiffness included as
covariates in the model will be fitted. A secondary
analysis will also be conducted using a longitudinal
repeated-measures analysis without the random state-
ment. The variables treatment group (with chlortalidone
as the reference group) and baseline arterial stiffness will
be included in the model as a covariates. The repeated
statement variable will be time. Analyses will be
conducted in Stata using the xtreg command or SAS
using the proc. mixed command.
Safety evaluation
The proportion of patients reporting hyperkalemia, a
decline in renal function (requiring discontinuation of
trial therapy), symptomatic hypotension (requiring dis-
continuation of trial therapy), and proportion of patients
reporting adverse effects (requiring discontinuation of
trial therapy) will be analyzed as categorical variables
using a χ2 test, with relative risks and 95% CIs reported.
The proportion of patients who died and the proportion
of patients who experienced a cardiovascular event will
be compared in the 2 treatment groups. A relative risk
and 95% CI will be reported, but no hypothesis testing
will be performed.
Impact
For most subjects with early-stage CKD, the risk of
death greatly exceeds the risk of progression to end-stage
renal disease, and much of the premature mortality is dueto cardiovascular disease.29 There is a pressing need,
therefore, for research into treatments to reduce the
cardiovascular mortality and morbidity of this high-risk
group. Published randomized trials of treatments to reduce
cardiovascular risk in subjects with early-stage CKD are
few. In the SHARP trial, statins reduced atherosclerotic
events but had a disappointing impact on total cardiovas-
cular mortality, suggesting that much cardiovascular
disease in CKD is not atherosclerotic.30 This result is in
line with epidemiological data suggesting that, in CKD,
sudden death, heart failure, and stroke are much more
common than myocardial infarction.4 Although ACE
inhibitors are commonly used in subjects with CKD and
may have risk-reducing effects similar to those seen in the
general population, physicians have tended to avoid MRB
drugs because of concerns about hyperkalemia.
In a previous study, we showed that LV mass and
arterial stiffness were improved with spironolactone with
few hyperkalemic problems in subjects with stages 2 and
3 CKD under close monitoring. This trial will further
examine the use of spironolactone in a similar cohort and
will specifically test the hypothesis that the effects of
spironolactone on LV mass demonstrated in the CRIB-2
study were due to specific MRB-mediated effects and not
to nonspecific blood pressure–lowering effects. This
hypothesis has biological plausibility in view of the
known cardiovascular inflammatory, fibrotic, and hyper-
trophic actions of aldosterone and the antagonistic effects
of MRB drugs on these processes.12 Furthermore, in the
4E study of subjects with LVH, the addition of eplerenone
to enalapril caused significant reduction in LV mass with
little effect on blood pressure.31 Cardiac MRI is the
method of choice for determining changes in LV mass in
response to treatment because of its high interstudy
reproducibility, lack of dependence on geometric as-
sumptions, and independence of changes in volume.32,33
Spironolactone may be a powerful treatment to reverse or
delay the onset of LVH and myocardial fibrosis in patients
with CKD. As both hypertrophy and fibrosis are likely key
intermediate phenotypic changes that result in an increased
risk of heart failure and arrhythmia in many patient groups,
the datawill be of great value in establishing amodeof action
of these drugs thatmaybe relevant to subjectswithCKDand
other at-risk groups.34 The range of secondary end points
including arterial stiffness, aortic distensibility, LV fibrosis,
systolic and diastolic function, kidney function, and
biomarkers may also provide powerful evidence of differ-
ences in the effects of MRB and diuretic drugs.
The effect of thiazide-like drugs on LV mass in
early-stage CKD has not previously been examined,
although they are effective in lowering blood pressure
in this group. The study will also provide evidence on the
safety of both spironolactone and chlorthalidone in
subjects with early-stage CKD, giving valuable data on
the effects of both drugs on kidney function measured by
eGFR and on changes in serum potassium and sodium
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Volume 191, Number 0concentrations. If safety and efficacy are confirmed, the
rationale would be provided for a larger clinical trial
designed to examine the effects of MRB drugs on
cardiovascular morbidity and mortality end points. It is
acknowledged that the nonblinded study design in-
creases the risk of bias, but the PROBE design maintains
the benefits associated with a strict randomization
procedure, whereas the blinded end points help
to eliminate bias. In a meta-analysis of trials of an
ARB, changes in mean 24-hour ambulatory blood
pressure in double-blind and PROBE trials were not
significantly different.35Acknowledgements
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